29th Aug 2019 08:16
(Alliance News) - Dechra Pharmaceuticals PLC on Thursday said it has acquired veterinary contract manufacturer Ampharmco LLC for USD30.0 Million in cash.
Veterinary pharmaceuticals firm Dechra has acquired Ampharmco, its Dragon Fire Holdings LLC and Black Griffin Holdings LLC holding companies, and its Texas-based manufacturing site.
Ampharmco was founded in 1999 and is based in Texas and has US Food & Drug Administration approval for two generic veterinary products.
These generics include the Gentamicin-Betamethasone Topical Spray, which is currently marketed by Dechra. The other generic is Carprofen Chewable Tablets, which is marketed by a different animal health firm.
The acquisition of Ampharmco's manufacturing facility also means Dechra will possess "an FDA-registered facility to manufacture solid dose, liquids, creams and ointments". This will strengthen Dechra's US manufacturing capability.
Dechra Chief Executive Ian Page said: "We are pleased to have completed the acquisition of [Ampharmco] which allows us to bring in-house manufacturing for a number of our currently outsourced products in the US market and will, in the longer term, also add to our US portfolio of approved [companion animal products]."
Shares in Dechra were up 1.1% at 2,998.00 pence in London early on Thursday morning.
Related Shares:
DPH.L